STAT reports on Eli Lilly's top spot in innovation and invention rankings, highlighting its strong performance in drug development.
Good morning. I'm feeling jealous of my colleagues who get to enjoy some good weather today in San Francisco for our Breakthrough West Summit. The need-to-know this morning Relay Therapeutics reported promising Phase 2 data of its drug zovegalisib in a group of rare diseases that cause abnormal vasculature development, sending company shares up 9% in premarket trading.
In a prominent analysis of drugmakers' R&D activity, the consulting firm IDEA Pharma has ranked companies on innovation and invention. This is the first time one company has topped both categories. Eli Lilly tops peers on R&D performance according to the report, ranking first in both innovation and invention metrics.
IDEA Pharma's rankings take into account revenue from new drugs for innovation and the number of drugs a company has in development along with its R&D investment for invention. The findings suggest that Eli Lilly is excelling not only in bringing novel treatments to market but also in investing heavily in research and development, which could be driving its strong performance.
To read more about this ranking and its implications for the pharmaceutical industry, continue to STAT+…
